焦點科技(002315.SZ):控股股東、監事完成減持 合計減持208.22萬股
格隆匯2月20日丨焦點科技(002315.SZ)公佈,公司近日收到控股股東沈錦華、監事李麗潔分別出具的《關於完成減持股份計劃的告知函》,沈錦華、李麗潔減持股份計劃已實施完成。沈錦華於2020年2月18日及19日通過集中競價方式減持公司股份206.2192萬股,佔公司總股本的0.8775%;李麗潔於2020年2月19日通過集中競價方式減持公司股份2萬股,佔公司總股本的0.0085%。
此次減持後,沈錦華持有公司股份1.2194億股,佔公司總股本的51.8905%;李麗潔持有公司股份8.0402萬股,佔公司總股本的0.0342%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.